5,852 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Meeder Asset Management Inc.

Share on StockTwits

Meeder Asset Management Inc. purchased a new position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,852 shares of the biopharmaceutical company’s stock, valued at approximately $73,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Marshall Wace LLP boosted its stake in shares of Amicus Therapeutics by 6.9% during the first quarter. Marshall Wace LLP now owns 169,001 shares of the biopharmaceutical company’s stock valued at $2,299,000 after purchasing an additional 10,911 shares during the period. DekaBank Deutsche Girozentrale raised its holdings in shares of Amicus Therapeutics by 266.2% in the second quarter. DekaBank Deutsche Girozentrale now owns 244,600 shares of the biopharmaceutical company’s stock valued at $2,935,000 after acquiring an additional 177,800 shares in the last quarter. Spark Investment Management LLC raised its holdings in shares of Amicus Therapeutics by 105.0% in the first quarter. Spark Investment Management LLC now owns 1,606,400 shares of the biopharmaceutical company’s stock valued at $21,847,000 after acquiring an additional 822,700 shares in the last quarter. Redmile Group LLC raised its holdings in shares of Amicus Therapeutics by 135.7% in the first quarter. Redmile Group LLC now owns 19,616,062 shares of the biopharmaceutical company’s stock valued at $266,778,000 after acquiring an additional 11,292,845 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in shares of Amicus Therapeutics by 2,637.6% in the first quarter. Bank of Montreal Can now owns 93,844 shares of the biopharmaceutical company’s stock valued at $1,276,000 after acquiring an additional 90,416 shares in the last quarter. Institutional investors own 95.01% of the company’s stock.

In other news, Director Michael Raab sold 5,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $11.16, for a total transaction of $55,800.00. Following the transaction, the director now owns 13,895 shares in the company, valued at $155,068.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Burke W. Whitman acquired 4,945 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were bought at an average price of $10.07 per share, for a total transaction of $49,796.15. Following the acquisition, the director now owns 21,612 shares of the company’s stock, valued at $217,632.84. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 65,000 shares of company stock worth $779,000. Corporate insiders own 2.50% of the company’s stock.

Shares of Amicus Therapeutics stock opened at $9.77 on Wednesday. The company has a market capitalization of $2.51 billion, a PE ratio of -7.35 and a beta of 1.85. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.97 and a current ratio of 7.09. The company has a 50-day simple moving average of $11.58 and a two-hundred day simple moving average of $12.39. Amicus Therapeutics, Inc. has a one year low of $8.27 and a one year high of $14.61.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.34) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.34). The business had revenue of $44.13 million during the quarter, compared to the consensus estimate of $41.14 million. Amicus Therapeutics had a negative net margin of 336.41% and a negative return on equity of 66.79%. The firm’s revenue was up 107.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.33) earnings per share. On average, equities analysts predict that Amicus Therapeutics, Inc. will post -1.3 earnings per share for the current fiscal year.

Several analysts recently weighed in on the company. BidaskClub downgraded Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 15th. ValuEngine downgraded Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. Cowen restated a “buy” rating and issued a $31.00 price objective on shares of Amicus Therapeutics in a report on Thursday, August 1st. Zacks Investment Research upgraded Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, May 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $19.00 price objective (down from $20.00) on shares of Amicus Therapeutics in a report on Wednesday, June 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $18.06.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.

Further Reading: Average Daily Trade Volume Explained

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Unibright  Price Hits $0.0116 on Exchanges
Unibright Price Hits $0.0116 on Exchanges
Analysts Set Calfrac Well Services Ltd  Target Price at C$3.53
Analysts Set Calfrac Well Services Ltd Target Price at C$3.53
$299.97 Million in Sales Expected for QEP Resources Inc  This Quarter
$299.97 Million in Sales Expected for QEP Resources Inc This Quarter
WABnetwork Trading Down 0.4% Over Last 7 Days
WABnetwork Trading Down 0.4% Over Last 7 Days
Authorship  Hits 24 Hour Volume of $20.00
Authorship Hits 24 Hour Volume of $20.00
Graphcoin  Market Cap Achieves $1,320.00
Graphcoin Market Cap Achieves $1,320.00


© 2006-2019 Ticker Report